Blue Yonder Announces Binding Agreement To Acquire One Network Enterprises for Approximately $839 Million To Create Multi-Enterprise Supply Chain Ecosystem
Blue Yonder, a leader in digital supply chain transformations, continues its forward momentum to revolutionize the supply chain and has today announced the signing of an agreement to acquire One Network Enterprises (One Network) for approximately $839 million, subject to adjustments. One Network, provider of the Digital Supply Chain Network™, is known for its autonomous and resilience services and is a leading global provider of intelligent control towers. Upon completion, Blue Yonder will be well positioned to serve customers’ needs across planning, execution, commerce, and networks.
“Supply chains have become more complex, and as more and more companies reduce risk by diversifying sourcing of products globally, there is an increased demand for the sharing of information and resources across the whole value chain. This, along with increased disruptions and geopolitical risks, have put the pressure on organizations to build more resilient and robust supply chains,” said Duncan Angove, CEO, Blue Yonder. “Combined with One Network’s capabilities, Blue Yonder will establish itself as a leading supply chain solutions company that can offer a unified, end-to-end supply chain ecosystem that is resilient enough to withstand today’s challenges, and synthesized with innovative, future-focused technologies.”
The combination of One Network’s Digital Supply Chain Network™ and Blue Yonder’s supply chain capabilities create an ecosystem that:
- Offers real-time, multi-enterprise optimization, orchestration, and collaboration both inside and outside an organization – across multi-tiers from customers to carriers to suppliers to the suppliers’ suppliers.
- Allows customers to move from the order planning phase to the fulfillment phase instantly, eliminating the time gap that normally occurs from entering the order to beginning the physical fulfillment. Customers can also tap into a more complete and actionable data set across the multi-enterprise ecosystem by setting up alerts, benefiting from automation, and leveraging generative artificial intelligence (AI).
- Provides real-time visibility across the supply chain, allowing customers to take immediate action via upstream and downstream collaboration.
- Unifies disparate data silos, enabling a holistic, executive-level view into the entire supply chain – resulting in the ability to automatically optimize and execute through prescriptive real-time decision-making technology.
In addition, carriers and suppliers will be able to leverage a range of services designed specifically for their needs, including: advanced shipment scheduling management, telematics tracking and predictive insights, real-time visibility to on-time delivery trends (by site, lane, carrier, distribution center), and the ability to manage by exception.
“Supply chains continue to be fragmented and overwhelmed with disruptions. What’s needed is a unified platform that enables multi-tier orchestration, planning, and collaboration that accelerates processes with autonomous and semi-autonomous decision-making and execution across trading partners. This is the next step to creating a resilient and collaborative supply chain,” said Greg Brady, chairman and founder, One Network. “Blue Yonder offers the most complete portfolio in the industry, spanning from planning to execution. Coupled with our network and multi-enterprise, multi-tier platform, we’re poised to form a backbone of this new supply chain of the future.”
By tapping into One Network’s revolutionary platform and multi-party network, leveraged by over 150,000 trading partners, Blue Yonder’s customers will benefit from an ecosystem that:
- Accelerates end-to-end decision-making, with increased visibility into materials, resources, loads, routes, and capacity.
- Offers real-time insights and predictions, enabling the ability to take action across the supply chain ecosystem, leading to fewer disruptions and a more resilient supply chain.
- Shares data seamlessly across the entire multi-tier supply chain, including suppliers and carriers, allowing for streamlined insights into potential disruptions and the ability to mitigate risk.
- Improves supplier and carrier collaboration processes – from order creation through scheduling and fulfillment – from days to minutes, removing inaccuracies, reducing time, and decreasing cost.
- Enables the journey to autonomous supply chain management through Smart Prescriptions™, adaptive flows, and interactive visualizations, powered by proprietary AI technology.
The closing of the transaction is subject to the satisfaction of customary conditions precedent in transactions of this type, including necessary regulatory approvals, and is expected to occur in Q2 or Q3 2024. This deal is indicative of Blue Yonder's momentum in the supply chain management space, and when completed, will mark approximately $1 billion in M&A investments covering three acquisitions since Q4 2023. This announcement comes on the heels of Blue Yonder’s acquisition of flexis, offering factory planning, sequencing, and slotting capabilities, and Doddle, offering returns management and reverse logistics solutions.
About One Network Enterprises
One Network Enterprises (ONE) is a leading global provider of intelligent control towers and the Digital Supply Chain Network™. Its solutions give supply chain managers and executives end-to-end visibility and control with one data model and one truth, from raw material to last-mile delivery. Powered by NEO, One Network’s machine learning and intelligent agent technology, it enables seamless planning and execution, across inbound supply, outbound order fulfillment, and logistics, matching demand with available supply in real-time. Lead your industry by providing the highest service levels and product quality at the lowest possible cost. Visit: www.onenetwork.com
About Blue Yonder
Blue Yonder is a world leader in digital supply chain transformation. Global retailers, manufacturers, and logistics providers leverage Blue Yonder to optimize their supply chains from planning through fulfillment, delivery, and returns. Blue Yonder’s AI-embedded, interoperable supply chain solutions are connected end-to-end via a unified platform and data cloud, enabling business to collaborate in real time across functions, which supports more agile decision-making, improved customer satisfaction, profitable growth, and more resilient, sustainable supply chains. Blue Yonder – Fulfill your Potential™ blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks, or service marks of the companies with which they are associated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328293246/en/
Contact information
Blue Yonder Public Relations Contacts:
Marina Renneke, APR, Global Corporate Communications Sr. Director
Tel: +1 480-308-3037, marina.renneke@blueyonder.com
Rossella Benti, EMEA Corporate Communications Director
Tel: +39 335 7849149, rossella.benti@blueyonder.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
